Sanofi

Stocks

SAN

FR0000120578

Real-time Euronext Paris Other stock markets 07:27:15 21/07/26 pm AEST			5-day change	1st Jan Change
76.96 ^EUR	+0.07%		+1.95%	-6.95%

21/07	SANOFI : Gets a Neutral rating from JP Morgan	ZD
21/07	European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading	MT

Transcript : Sanofi - Special Call

Published on 12/17/2025 at 05:20 am AEDT - Modified on 12/17/2025 at 01:50 pm AEDT

S&P Capital IQ

Add MarketScreener to your sources

Presenter Speech
Thomas Larsen (Executives)

Good afternoon and good morning, depending on where you are, and welcome to the Sanofi's first year-end late-stage pipeline review. I'm Thomas Kudsk Larsen

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Add MarketScreener to your sources

Latest news about Sanofi

21/07	SANOFI : Gets a Neutral rating from JP Morgan	ZD
21/07	European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading	MT
20/07	Eli Lilly May Raise Stake in Scribe Therapeutics to 10.9% Through IPO	MT
20/07	Eli Lilly May Raise Stake in Scribe Therapeutics to 10.9% Stake Through IPO	MT
20/07	Scribe Therapeutics to Sell 7.15 Million Shares at $13-$15 Each in IPO	DJ
17/07	Sanofi strengthens its research alliance with Aqemia
17/07	Aqemia and Sanofi Expand Research Collaboration	CI
16/07	Merck gets US FDA nod for first-in-its-class oral cholesterol drug	RE
15/07	European Equities Traded in the US as American Depositary Receipts Rise Tuesday	MT
15/07	Where would AI lead Pharma in the long run?
14/07	AlphaValue/Baader Europe Downgrades Sanofi to Add, Trims PT	MT
13/07	SANOFI : UBS reiterates its Neutral rating	ZD
13/07	EXECUTIVE CHANGES: Rank Group confirms interim CEO Harris as permanent	AN
11/07	Sanofi Receives Fda Approval for Subcutaneous Sarclisa Escena Administered Via On-Body Injector	CI
11/07	Sanofi Wins US FDA Approval for Subcutaneous Sarclisa Escena in Multiple Myeloma	MT